TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023

Globe Newswire 14-Jul-2023 7:05 AM

HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV, "the Company"))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success being held virtually on July 18, 2023.

William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success
Format: Fireside Chat with Aravive (ARAV)
Date/Time: Tuesday, July 18, 2023 at 12:00-12:45 PM ET
Host: Andy Hsieh, Ph.D., Biotech Research Analyst, William Blair
Presenter: Gail McIntyre, Ph.D., DABT, CEO, Aravive
Webcast: Conference attendees can check the schedule for more details or reach out to their William Blair salesperson.
  

A replay of the session will be available for 7 days following the event through the Aravive Events & Presentations section of the website https://ir.aravive.com/events-and-presentations.

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com.

Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Image for Press Release 1733762
Image for Press Release 1733762

Primary Logo